Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue was flat, EPS fell 296.0%, free cash flow grew 121.4% and total debt fell 3.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

41.52 0.41 +1.00%
Market cap
$47.9B
P/E
65.9×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
9.69% 21.58% 21.21% 10.44%

+8 more TTM periods

Piotroski F-Score
7 7 8 7
ROA
1.77% 3.99% 3.52% 1.74%
ROIC
4.58% 6.77% 6.37% 7.84%
Return on Tangible Assets
34.62% 37.48% 30.85% 11.74%
Average Days of Receivables
73.63 71.38 78.44 82.90
Free Cash Flow per Share
1.20 1.06 1.03 0.54
Free Cash Flow
1,401.00 1,231.00 1,182.00 616.00
Other line items

Show all line items

Columns are period end dates